尚荣医疗
(002551)
| 流通市值：27.75亿 | | | 总市值：38.39亿 |
| 流通股本：6.11亿 | | | 总股本：8.45亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 528,042,409.63 | 279,741,529.44 | 1,448,206,268.39 | 1,002,639,030.84 |
| 营业收入 | 528,042,409.63 | 279,741,529.44 | 1,448,206,268.39 | 1,002,639,030.84 |
| 二、营业总成本 | 554,274,104.42 | 283,907,062.28 | 1,385,050,001.21 | 990,946,064.65 |
| 营业成本 | 441,091,432.86 | 237,019,686.94 | 1,188,953,686.35 | 843,830,113.81 |
| 税金及附加 | 14,733,612.24 | 5,724,769.63 | 22,465,222.76 | 15,273,208.2 |
| 销售费用 | 8,725,117.65 | 3,821,439.95 | 16,073,186.74 | 11,448,990.8 |
| 管理费用 | 69,110,261.1 | 33,921,138.26 | 132,993,791.04 | 107,863,929.34 |
| 研发费用 | 20,173,329.07 | 10,064,345.68 | 40,783,991.67 | 29,181,706.49 |
| 财务费用 | 440,351.5 | -6,644,318.18 | -16,219,877.35 | -16,651,883.99 |
| 其中:利息费用 | 13,443,810.73 | 968,478.8 | 5,828,053.65 | 1,788,712.36 |
| 其中:利息收入 | 4,897,069.22 | 1,477,585.18 | 10,764,801.48 | 7,712,636.19 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -3,638,102.83 | -919,641.25 | 1,322,766.63 | 816,281.21 |
| 加:投资收益 | 7,087,511.07 | 2,964,577.49 | 2,701,178.47 | 1,476,489.13 |
| 资产处置收益 | 3,104.67 | 3,106.5 | 124,830.39 | 79,580.87 |
| 资产减值损失(新) | 10,253.94 | 9,916.72 | -9,154,823.65 | 1,552,679.83 |
| 信用减值损失(新) | 17,312,590.11 | 25,797,294.22 | -29,835,989.98 | -7,580,371.28 |
| 其他收益 | 1,733,681.91 | 900,757.74 | 5,223,044.58 | 2,977,073.61 |
| 四、营业利润 | -3,722,655.92 | 24,590,478.58 | 33,537,273.62 | 11,014,699.56 |
| 加:营业外收入 | 1,095,560.09 | 187,926.28 | 6,220,965.74 | 10,077,979.72 |
| 减:营业外支出 | 393,715.98 | 242,222.25 | 6,154,699.75 | 537,576.14 |
| 五、利润总额 | -3,020,811.81 | 24,536,182.61 | 33,603,539.61 | 20,555,103.14 |
| 减:所得税费用 | 1,499,341.75 | 7,489,988.41 | 7,691,020.41 | 1,960,864.39 |
| 六、净利润 | -4,520,153.56 | 17,046,194.2 | 25,912,519.2 | 18,594,238.75 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -4,520,153.56 | 17,046,194.2 | 25,912,519.2 | 18,594,238.75 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -7,758,226.19 | 13,964,187.65 | 22,281,952.68 | 14,727,598.37 |
| 少数股东损益 | 3,238,072.63 | 3,082,006.55 | 3,630,566.52 | 3,866,640.38 |
| 扣除非经常损益后的净利润 | -12,518,689.29 | 11,703,692.54 | 11,658,106.74 | 3,422,760.8 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.01 | 0.02 | 0.03 | 0.02 |
| (二)稀释每股收益 | -0.01 | 0.02 | 0.03 | 0.02 |
| 八、其他综合收益 | -4,231,991.86 | -2,862,041.24 | 5,093,558.79 | -2,006,874.66 |
| 归属于母公司股东的其他综合收益 | -5,302,067.94 | -4,001,937.53 | 5,569,518.82 | -4,584,700.94 |
| 九、综合收益总额 | -8,752,145.42 | 14,184,152.96 | 31,006,077.99 | 16,587,364.09 |
| 归属于母公司股东的综合收益总额 | -13,060,294.13 | 9,962,250.12 | 27,851,471.5 | 10,142,897.43 |
| 归属于少数股东的综合收益总额 | 4,308,148.71 | 4,221,902.84 | 3,154,606.49 | 6,444,466.66 |
| 公告日期 | 2025-08-26 | 2025-04-29 | 2025-04-29 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |